The effect of internalizing human single chain antibody fragment on liposome targeting to epithelioid and sarcomatoid mesothelioma

Biomaterials

Volumn 32, Issue 10, 2011, Pages 2605-2613

  Iyer, Arun K ^a   Su, Yang ^a   Feng, Jinjin ^a   Lan, Xiaoli ^a   Zhu, Xiaodong ^a   Liu, Yue ^a   Gao, Dongwei ^a   Seo, Youngho ^a   VanBrocklin, Henry F ^a,b   Courtney Broaddus, V ^a,b   Liu, Bin ^a,b   He, Jiang ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Immunoliposomes; Mesothelioma; ScFv antibody; SPECT CT imaging; Tumor targeting

Indexed keywords

IMMUNOLIPOSOMES; MESOTHELIOMA; SCFV ANTIBODY; SPECT/CT; TUMOR TARGETING;

ANTIBODIES; BEARINGS (STRUCTURAL); CELL CULTURE; DISEASE CONTROL; LIPOSOMES; NUCLEAR MEDICINE; PHOSPHOLIPIDS; SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY; TOMOGRAPHY;

TUMORS;

IMMUNOLIPOSOME; INDIUM 111; LIPOSOME; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DRUG BINDING; DRUG DISTRIBUTION; EPITHELIOID MESOTHELIOMA; HUMAN; HUMAN CELL; MALE; MESOTHELIOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; SARCOMATOID MESOTHELIOMA; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ANIMALS; DRUG DELIVERY SYSTEMS; ENDOCYTOSIS; HUMANS; HYDRODYNAMICS; INDIUM RADIOISOTOPES; LIPOSOMES; MESOTHELIOMA; MICE; PARTICLE SIZE; SARCOMA; SINGLE-CHAIN ANTIBODIES; STATIC ELECTRICITY; TISSUE DISTRIBUTION; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TOMOGRAPHY, X-RAY COMPUTED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

ANIMALIA; MUS;

EID: 79251595316     PISSN: 01429612     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2010.11.073     Document Type: Article

References (58)

1. Sterman D.H., Recio A., Haas A.R., Vachani A., Katz S.I., Gillespie C.T., et al. A Phase I trial of repeated intrapleural adenoviral-mediated interferon-beta gene transfer for mesothelioma and metastatic pleural effusions. Mol Ther 2010, 18:852-860.
2. Curran D., Sahmoud T., Therasse P., Van Meerbeeck J., Postmus P., Giaccone G. Prognostic factors in patients with pleural mesothelioma: the European organization for research and treatment of cancer experience. J Clin Oncol 1998, 16:145-152.
3. Bianchi C., Bianchi T. Malignant mesothelioma: global incidence and relationship with asbestos. Ind Health 2007, 45:379-387.
4. Smith A., Wright C. Chrysotile asbestos is the main cause of pleural mesothelioma. Am J Ind Med 1996, 30:252-266.
5. Dunleavey R. Malignant mesothelioma: risk factors and current management. Nurs Times 2004, 100:40-43.
6. Churg A., Roggli V., Galateau-Salle F., Cagle P., Gibbs A., Hasleton P., et al. Mesothelioma. Pathology and genetics tumours of the lung, pleura, thymus and heart 2004, 125-136. IARC, Lyon. W. Travis, E. Brambilla, H. Muller-Hermelink, C. Harris (Eds.).
7. Attanoos R., Gibbs A. Pathology of malignant mesothelioma. Histopathology 1997, 30:403-418.
8. Ho L., Sugarbaker D., Skarin A. Malignant pleural mesothelioma. Cancer Treat Res 2001, 105:327-373.
9. Butchart E. Contemporary management of malignant pleural mesothelioma. Oncologist 1999, 4:488-500.
10. Klebe S., Brownlee N., Mahar A., Burchette J., Sporn T., Vollmer R., et al. Sarcomatoid mesothelioma: a clinical-pathologic correlation of 326 cases. Mod Pathol 2010, 23:470-479.
11. Torchilin V. Multifunctional nanocarriers. Adv Drug Deliv Rev 2006, 58:1532-1555.
12. Farokhzad O., Langer R. Nanomedicine: developing smarter therapeutic and diagnostic modalities. Adv Drug Deliv Rev 2006, 58:1456-1459.
13. Papahadjopoulos D., Allen T., Gabizon A., Mayhew E., Matthay K., Huang S., et al. Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc Natl Acad Sci U S A 1991, 88:11460-11464.
14. Allen T. Long-circulating (sterically stabilized) liposomes for targeted drug delivery. Trends Pharmacol Sci 1994, 15:215-220.
15. Maeda H., Wu J., Sawa T., Matsumura Y., Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 2000, 65:271-284.
16. Iyer A.K., Khaled G., Fang J., Maeda H. Exploiting the enhanced permeability and retention effect for tumor targeting. Drug Discov Today 2006, 11:812-818.
17. Nielsen U., Kirpotin D., Pickering E., Hong K., Park J., Refaat Shalaby M., et al. Therapeutic efficacy of anti-ErbB2 immunoliposomes targeted by a phage antibody selected for cellular endocytosis. Biochim Biophys Acta 2002, 1591:109-118.
18. Kweon S., Lee H.J., Hyung W.J., Suh J., Lim J.S., Lim S.J. Liposomes coloaded with iopamidol/lipiodol as a RES-targeted contrast agent for computed tomography imaging. Pharm Res 2010, 27:1408-1415.
19. Jiang J., Yang S.J., Wang J.C., Yang L.J., Xu Z.Z., Yang T., et al. Sequential treatment of drug-resistant tumors with RGD-modified liposomes containing siRNA or doxorubicin. Eur J Pharm Biopharm 2010, 76:170-178.
20. An F., Drummond D., Wilson S., Kirpotin D., Nishimura S., Broaddus V., et al. Targeted drug delivery to mesothelioma cells using functionally selected internalizing human single-chain antibodies. Mol Cancer Ther 2008, 7:569-578.
21. Bidlingmaier S., He J., Wang Y., An F., Feng J., Barbone D., et al. Identification of MCAM/CD146 as the target antigen of a human monoclonal antibody that recognizes both epithelioid and sarcomatoid types of mesothelioma. Cancer Res 2009, 69:1570-1577.
22. Liu B., Conrad F., Cooperberg M., Kirpotin D., Marks J. Mapping tumor epitope space by direct selection of single-chain Fv antibody libraries on prostate cancer cells. Cancer Res 2004, 64:704-710.
23. MacDonald R., MacDonald R., Menco B., Takeshita K., Subbarao N., Hu L. Small-volume extrusion apparatus for preparation of large, unilamellar vesicles. Biochim Biophys Acta 1991, 1061:297-303.
24. Bartlett G. Phosphorus assay in column chromatography. J Biol Chem 1959, 234:466-468.
25. Kirpotin D., Park J., Hong K., Zalipsky S., Li W., Carter P., et al. Sterically stabilized anti-HER2 immunoliposomes: design and targeting to human breast cancer cells in vitro. Biochemistry 1997, 36:66-75.
26. Park J., Hong K., Kirpotin D., Colbern G., Shalaby R., Baselga J., et al. Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. Clin Cancer Res 2002, 8:1172-1181.
27. Iden D., Allen T. In vitro and in vivo comparison of immunoliposomes made by conventional coupling techniques with those made by a new post-insertion approach. Biochim Biophys Acta 2001, 1513:207-216.
28. Ellman G. Tissue sulfhydryl groups. Arch Biochem Biophys 1959, 82:70-77.
29. Mougin-Degraef M., Bourdeau C., Jestin E., Saï-Maurel C., Bourgeois M., Saëc P.R., et al. Doubly radiolabeled liposomes for pretargeted radioimmunotherapy. Int J Pharm 2007, 344:110-117.
30. Dhalluin X., Scherpereel A. Treatment of malignant pleural mesothelioma: current status and future directions. Monaldi Arch Chest Dis 2010, 73:79-85.
31. Skubitz K. Phase II trial of pegylated-liposomal doxorubicin (doxil) in mesothelioma 1. Cancer Invest 2002, 20:693-699.
32. Steele J., O'Doherty C., Shamash J., Evans M., Gower N., Tischkowitz M., et al. Phase II trial of liposomal daunorubicin in malignant pleural mesothelioma. Ann Oncol 2001, 12:497-499.
33. Baas P., Van Meerbeeck J., Groen H., Schouwink H., Burgers S., Daamen S., et al. CaelyxTM in malignant mesothelioma: a phase II EORTC study. Ann Oncol 2000, 11:697-700.
34. Lu C., Perez-Soler R., Piperdi B., Walsh G., Swisher S., Smythe W., et al. Phase II study of a liposome-entrapped cisplatin analog (L-NDDP) administered intrapleurally and pathologic response rates in patients with malignant pleural mesothelioma. J Clin Oncol 2005, 23:3495-3501.
35. Park J., Hong K., Kirpotin D., Papahadjopoulos D., Benz C.C. Immunoliposomes for cancer treatment. Adv Pharmacol 1997, 40:399-435.
36. Kontermann R. Immunoliposomes for cancer therapy. Curr Opin Mol Ther 2006, 8:39-45.
37. Hertlein E., Triantafillou G., Sass E.J., Hessler J.D., Zhang X., Jarjoura D., et al. Milatuzumab immunoliposomes induce cell death in CLL by promoting accumulation of CD74 on the surface of B cells. Blood 2010, 116:2554-2558.
38. Moase E., Qi W., Ishida T., Gabos Z., Longenecker B., Zimmermann G., et al. Anti-MUC-1 immunoliposomal doxorubicin in the treatment of murine models of metastatic breast cancer. Biochim Biophys Acta 2001, 1510:43-55.
39. Park J., Hong K., Carter P., Asgari H., Guo L., Keller G., et al. Development of anti-p185HER2 immunoliposomes for cancer therapy. Proc Natl Acad Sci U S A 1995, 92:1327-1331.
40. Bendas G. Immunoliposomes: a promising approach to targeting cancer therapy. BioDrugs 2001, 15:215-224.
41. Szoka F., Papahadjopoulos D. Comparative properties and methods of preparation of lipid vesicles (liposomes). Annu Rev Biophys Bioeng 1980, 9:467-508.
42. Templeton N., Lasic D. New directions in liposome gene delivery. Mol Biotechnol 1999, 11:175-180.
43. Barenholz Y. Liposome application: problems and prospects. Curr Opin Colloid Interface Sci 2001, 6:66-77.
44. Hansen C., Kao G., Moase E., Zalipsky S., Allen T. Attachment of antibodies to sterically stabilized liposomes: evaluation, comparison and optimization of coupling procedures. Biochim Biophys Acta 1995, 1239:133-144.
45. Allen T., Agrawal A., Ahmad I., Hansen C., Zalipsky S. Antibody-mediated targeting of long-circulating (stealth) liposomes. J Liposome Res 1994, 4:1-25.
46. Maruyama K., Takizawa T., Yuda T., Kennel S., Huang L., Iwatsuru M. Targetability of novel immunoliposomes modified with amphipathic poly (ethylene glycol) s conjugated at their distal terminals to monoclonal antibodies. Biochim Biophys Acta 1995, 1234:74-80.
47. Martin F., Hubbell W., Papahadjopoulos D. Immunospecific targeting of liposomes to cells: a novel and efficient method for covalent attachment of Fab' fragments via disulfide bonds. Biochemistry 1981, 20:4229-4238.
48. Moreira J., Ishida T., Gaspar R., Allen T. Use of the post-insertion technique to insert peptide ligands into pre-formed stealth liposomes with retention of binding activity and cytotoxicity. Pharm Res 2002, 19:265-269.
49. Scatchard G. The attraction of proteins for small molecules. Ann NY Acad Sci 1949, 51:660-672.
50. Sullivan S., Huang L. Preparation and characterization of heat-sensitive immunoliposomes. Biochim Biophys Acta 1985, 812:116-126.
51. Babbitt B., Huang L. Effects of valency on thermodynamic parameters of specific membrane interaction. Biochemistry 1985, 24:2186-2194.
52. Heath T., Fraley R., Bentz J., Voss E.W., Herron J., Papahadjopoulos D. Antibody-directed liposomes determination of affinity constants for soluble and liposome-bound antifluorescein. Biochim Biophys Acta 1984, 770:148-158.
53. Maruyama K., Kennel S., Huang L. Lipid composition is important for highly efficient target binding and retention of immunoliposomes. Proc Natl Acad Sci U S A 1990, 87:5744-5748.
54. Ahmad I., Allen T. Antibody-mediated specific binding and cytotoxicity of liposome-entrapped doxorubicin to lung cancer cells in vitro. Cancer Res 1992, 52:4817-4820.
55. Mishra S., Webster P., Davis M. PEGylation significantly affects cellular uptake and intracellular trafficking of non-viral gene delivery particles. Eur J Cell Biol 2004, 83:97-111.
56. Hong R., Huang C., Tseng Y., Pang V., Chen S., Liu J., et al. Direct comparison of liposomal doxorubicin with or without polyethylene glycol coating in C-26 tumor-bearing mice. Clin Cancer Res 1999, 5:3645-3652.
57. Torchilin V., Klibanov A., Huang L., O'Donnell S., Nossiff N., Khaw B. Targeted accumulation of polyethylene glycol-coated immunoliposomes in infarcted rabbit myocardium. FASEB J 1992, 6:2716-2719.
58. De Menezes L., Daniel E., Pilarski L., Allen T. In vitro and in vivo targeting of immunoliposomal doxorubicin to human B-cell lymphoma. Cancer Res 1998, 58:3320-3330.